Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women

Opioid Use Disorder Clinical Trial

Official title:

Long Acting Subcutaneous Compared to Short Acting Sublingual Buprenorphine Administration in Pregnant and Lactating Women

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04212065
• Other study ID #: 2019H0354
• Status: Withdrawn
• Phase: Phase 4
• Start date: February 21, 2020
• Est. completion date: September 1, 2020

Study information

• Verified date: October 2020
• Source: Ohio State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a non-inferiority, open label, randomized trial of women on buprenorphine Medication Assisted Therapy for opioid use disorder in pregnancy.Patients will be randomized to either the long acting monthly subcutaneous SublocadeTM or to short acting sublingual Suboxone®.

Description:

Opioid use disorder increased among pregnant women in recent years, despite an overall decrease in the general population in the same time frame. Given the increased use of buprenorphine for opioid use disorder, it has now become the most commonly misused prescription opioid subtype. Untreated opioid use disorder is associated with worse maternal, fetal, and neonatal outcomes. To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 1, 2020
• Est. primary completion date: September 1, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 41 Years

Eligibility

Inclusion Criteria:

• Age 18-41 years

• Women with a viable singleton or twin intrauterine pregnancy between 14 0/7 and 27 6/7 weeks gestation based on the best obstetric estimate by ACOG (The American College of Obstetricians and Gynecologists) criteria, and are not planning to terminate the pregnancy.

• Diagnosis of moderate to severe Opioid Use Disorder (OUD), as defined by DSM-V criteria. Mild OUD is defined as 2-3 of the following present, moderate OUD with 4-5 of the following present, and severe OUD with 6 or more of the following present:

• Substance is often taken in larger amounts and/or over a longer period than the patient intended.

• Persistent attempts or one or more unsuccessful efforts made to cut down or control substance use.

• A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from effects.

• Craving or strong desire or urge to use the substance

• Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home.

• Continued substance use despite having persistent or recurrent social or interpersonal problem caused or exacerbated by the effects of the substance.

• Important social, occupational or recreational activities given up or reduced because of substance use.

• Recurrent substance use in situations in which it is physically hazardous.

• Substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance.

The diagnosis and the diagnostic criteria will be recorded.

• Willing to be randomized to subcutaneous or sublingual buprenorphine and to comply with study procedures, including weekly Medication Check Visits

• Planning to deliver at OSU Wexner Medical Center

• Enrolled in prenatal outpatient addiction treatment at OSU

• Able to understand the study, and having understood, provide written informed consent in English

Exclusion Criteria:

• Known allergy or adverse reaction to buprenorphine

• Abnormal obstetrical ultrasound suspicious for major congenital abnormality

• Known or suspected fetal aneuploidy (by either CVS (Chorionic Villus Sampling), amniocentesis or cell-free DNA)

• Participation in another trial that may influence the primary outcome, without prior approval

• Participation in this trial in a prior pregnancy

• Higher order pregnancy

• Have a physiological dependence on alcohol or sedatives requiring medical detoxification

• Have a psychiatric condition that, in the judgment of the site medical clinician (MC), would make study participation unsafe or which would make treatment compliance difficult. Examples include:

• Suicidal or homicidal ideation requiring immediate attention

• Severe, inadequately-treated mental health disorder (e.g., active psychosis, uncontrolled bipolar disorder)

• Have a medical condition that, in the judgment of the study MC, would make study participation unsafe or which would make treatment compliance difficult. Medical conditions that may compromise participant safety or study conduct include, but are not limited to, allergy/sensitivity to study medications and the following based on clinical labs:

• aspartate aminotransferase (AST) / alanine aminotransferase (ALT) greater than 5X upper limit of normal

• serum creatinine greater than 1.5X upper limit of normal

• total bilirubin greater than 1.5X upper limit of normal

• Currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or other situation (e.g., unstable living arrangements) that, in the judgement of the site investigator, could prevent participation in the study or in any study activities;

• Currently receiving methadone or naltrexone for the treatment of OUD;

• Enrolled in or planning to enroll in treatment beyond the level of 3.1 (clinically managed low-intensity residential services) of the American Society of Addiction Medicine criteria

• Enrolled in or planning to enroll in: a) a trial testing medication for managing OUD during pregnancy; b) research testing an intervention for substance use disorder or NAS (Neonatal Abstinence Syndrome) in their infant unless they are willing to provide a release for the research records.

Related Conditions & MeSH terms

• Opioid Use Disorder

Intervention

Drug:
• buprenorphine
To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.

Locations

Country	Name	City	State
United States	The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Ohio State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluating the compliance with prescribed medication is not inferior in women assigned to SublocadeTM compared with those to Suboxone®.	Compliance will be assessed by urine drug screens during pregnancy and postpartum visits that are positive for buprenorphine, with assessment of the number of drug screens which are negative for illicit drugs out of the total collected during the study period, with a minimum of three drug screens collected.	Through study completion, an average of 1.5 years
Secondary	Evaluating concentration of buprenorphine and metabolites in maternal plasma	o A weekly blood draw will be collected, with evaluation of drug concentrations at approximate trough and peak levels before and after drug administration. The blood draw around the time of delivery will evaluate the association between drug concentration and neonatal opioid withdrawal syndrome outcomes.	Enrollment through four weeks postpartum
Secondary	Evaluating concentration of buprenorphine and metabolites in cord plasma	Cord blood will be collected and used to estimate fetal exposure to buprenorphine	Delivery
Secondary	Evaluating concentration of buprenorphine and metabolites in breast milk	Breast milk will be collected and used to estimate infant exposure to buprenorphine via breast milk	1-6 months postpartum